Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D47RUF
|
|||
| Drug Name |
REC-994
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Cerebral cavernous malformation [ICD-11: 8B22.41] | Phase 2 | [1] | |
| Company |
Recursion Pharmaceuticals Salt Lake City, UT
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05085561) A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.